#SARS-CoV-2

Full approval could encourage more people to get vaccinated and raises the prospect of off-label use.

The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.

Trial will assess antibody response in people who did not respond to two-dose regimen.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.

Molnupiravir, first developed for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.

People with immune deficiency may not respond as well to vaccines but could still gain some protection.

The CDC and FDA confirmed that the vaccine is safe, and said the recent pause should be lifted for all groups.

So far, the rise in COVID-related transplants has not dramatically affected the existing waiting lists for organs.

People with both obesity and liver steatosis were at greater risk for hospitalization with COVID-19.

Nearly two-thirds of COVID-19 hospitalizations in the U.S. could be attributed to obesity, diabetes, hypertension, and heart failure.

Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.

COVID-19 cases, hospitalizations and deaths continue to drop in the United States, but a global pandemic cannot be defeated in one country.